The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.
The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.
Jeewanjot Singh, Subhi Sharma, Prabhjot Singh et al.· Advances in Modern Biomedici...· 0 citations
This approach aims not only to control symptoms but also to potentially control neurodegeneration in PD, and the major challenges include large-scale production, long-term safety assessment, regulatory challenges, and site-specific delivery.
P. Gaur, Prachee Raje Bisht, Sonia Lal Gupta· Journal of Biomaterials Scie...· 0 citations
Overall, saponins represent a promising avenue for the development of novel neuroprotective and disease-modifying therapies for PD, and challenges such as poor bioavailability in natural sources and limited access to brain remain significant barriers to clinical translation.
Debasmita Tripathy, Shreya Sen Sarma, Deepak Kumar et al.· Neurochemistry International· 0 citations
This review focuses on the potential molecular mechanism underlying KLF4-mediated neuroinflammation, oxidative stress, mitochondrial dysfunction, and apoptosis and targeting them appears to be a viable therapeutic strategy for treating PD.
Anjali Kumari, K. Aran· Current Medical Science· 0 citations
A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...
Dipesh Kumar, Renuka Sahu, Naveen Kumar et al.· International Journal of Sci...· 0 citations
Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to striatal dopamine depletion and resulting motor (e.g., tremor, bradykinesia) and non-motor symptoms (e.g., cognitive decline and sleep abnormalities). Current treatm...
Lian-Cheng Zhi· Journal of Clinical Technolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
